216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors

Published 2008 View Full Article

Authors

Keywords

Journal

EJC SUPPLEMENTS

Volume 6, Issue 12, Pages 68-69

Publisher

Elsevier BV

Online

2008-10-22

DOI

10.1016/s1359-6349(08)72148-7

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

EJC SUPPLEMENTS

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.